, Volume 182, Issue 4, pp 588–596 | Cite as

Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats

  • Emily M. Jutkiewicz
  • Kenner C. Rice
  • John R. Traynor
  • James H. Woods
Original Investigation



Delta-opioid agonists produce a number of behavioral effects, including convulsions, antinociception, locomotor stimulation, and antidepressant-like effects. The development of these compounds as treatments for depression is limited by their convulsive effects. Therefore, determining how to separate the convulsive and antidepressant-like characteristics of these compounds is essential for their potential clinical use.


The present study tests the hypothesis that the rate of delta-opioid agonist administration greatly contributes to the convulsive properties, but not the antidepressant-like effects, of delta-opioid agonists.

Materials and methods

The delta-opioid agonist SNC80 (1, 3.2, and 10 mg kg−1 or vehicle) was administered to Sprague–Dawley rats by intravenous infusion over different durations of time (20 s, 20, or 60 min). Convulsions were measured by observation prior to determining antidepressant-like effects in the forced swim test.


Slowing the rate of SNC80 administration minimized delta agonist-induced convulsions without altering the effects of SNC80 in the forced swim test.


These data suggest that delta agonist-induced antidepressant properties are independent of convulsive effects, and that it may be possible to eliminate the convulsions produced by delta agonists, further promoting their potential clinical utility.


Delta-opioid receptor Antidepressants Convulsions Forced swim test Rats SNC80 Infusion rate 



This work was supported by grants from the US Public Health Service Grants DA00254, T32 GM07767, and T32 DA07267.


  1. Abreu ME, Bigelow GE, Fleisher L, Walsh SL (2001) Effects of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) 154:76–84CrossRefGoogle Scholar
  2. Baamonde A, Daugé V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournié-Zaluski MC, Roques BP (1992) Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid δ and dopamine D1 receptor stimulation. Eur J Pharmacol 216:157–166CrossRefPubMedGoogle Scholar
  3. Baird TJ, Deng S-X, Landry DW, Winger G, Woods JH (2000) Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J Pharmacol Exp Ther 295:1127–1134PubMedGoogle Scholar
  4. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002a) Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 26(6):744–755CrossRefPubMedGoogle Scholar
  5. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002b) Convulsant activity of a nonpeptidic delta-opioid receptor agonist is not required for antidepressant-like effects. Psychopharmacology (Berl) 164(1):42–48CrossRefGoogle Scholar
  6. Broom DC, Nitsche JF, Pintar JE, Rice KC, Woods JH, Traynor JR (2002c) Comparison of receptor mechanisms and efficacy requirements for δ-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 303:723–729CrossRefPubMedGoogle Scholar
  7. Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang KJ, DeCosta BR, Mosberg HI, Woods JH (1993) Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 267(2):888–895PubMedGoogle Scholar
  8. Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121:66–72CrossRefGoogle Scholar
  9. de Wit H, Dudish S, Ambre J (1993) Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology (Berl) 112:324–330CrossRefGoogle Scholar
  10. Dykstra LA, Schoenbaum GM, Yarbrough J, McNutt R, Chang K-J (1993) A novel δ-opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration. J Pharmacol Exp Ther 267:875–882PubMedGoogle Scholar
  11. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HWD, Simonin F, Befort K, Gavériaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nature 25:195–200Google Scholar
  12. Greenstein YJ, Pavlides C, Winson J (1998) Long-term potentiation in the dentate gyrus is preferentially induced at theta rhythm periodicity. Brain Res 438:331–334CrossRefGoogle Scholar
  13. Hong EJ, Rice KC, Calderon S, Woods JH, Traynor JR (1998) Convulsive behavior of nonpeptide δ-opioid ligands: comparison of SNC80 and BW373U86 in mice. Analgesia 3:269–276Google Scholar
  14. Jutkiewicz EM, Eller EB, Folk JE, Rice KC, Traynor JR, Woods JH (2004) δ-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague–Dawley rats. J Pharmacol Exp Ther 309(1):173–181CrossRefPubMedGoogle Scholar
  15. Kollins SH, Rush CR, Pazzaglia, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6(4):367–374CrossRefPubMedGoogle Scholar
  16. Larson J, Wong D, Lynch G (1986) Patterned stimulation at the theta frequency is optimal for the induction of hippocampal long-term potentiation. Brain Res 368:347–350CrossRefPubMedGoogle Scholar
  17. Law PY (2004) Delta opioid receptor signal trafficking. In: Chang K-J, Porreca F, Woods JH (eds) The delta receptor. Dekker, New York, pp 61–88Google Scholar
  18. Negus SS, Butelman ER, Chang K-J, DeCosta B, Winger G, Woods JH (1994) Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther 270:1025–1034Google Scholar
  19. Pakarinen ED, Woods JH, Moerschbaecher JM (1995) Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist. J Pharmacol Exp Ther 272:552–559PubMedGoogle Scholar
  20. Pollack GM, Shen DD (1985) A timed intravenous pentylenetetrazol infusion seizure model for quantifying the anticonvulsant effect of valproic acid in the rat. J Pharmacol Methods 13:135–146CrossRefPubMedGoogle Scholar
  21. Porrino LJ (1993) Functional consequences of acute cocaine treatment depend on route of administration. Psychopharmacology (Berl) 112:343–351CrossRefGoogle Scholar
  22. Samaha A-N, Li Y, Robinson TE (2002) The rate of intravenous cocaine administration determines susceptibility to sensitization. J Neurosci 22(8):3244–3250PubMedGoogle Scholar
  23. Schetz JA, Calderon SN, Bertha CM, Rice KC, Porreca F (1996) Rapid in vivo metabolism of a methylether derivative of (±)-BW373U86: the metabolic fate of [3H]SNC121 in rats. J Pharmacol Exp Ther 279:1069–1076PubMedGoogle Scholar
  24. Tejedor-Real P, Micó JA, Smadja C, Maldonado R, Roques BP, Gibert-Rahola J (1998) Involvement of δ-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 354:1–7CrossRefPubMedGoogle Scholar
  25. Tsukada M, Aihara T, Mizuno M, Kato H, Ito K (1994) Temporal pattern sensitivity of long-term potentiation in hippocampal CA1 neurons. Biol Cybern 70:495–503CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Emily M. Jutkiewicz
    • 1
  • Kenner C. Rice
    • 2
  • John R. Traynor
    • 1
  • James H. Woods
    • 1
  1. 1.Department of PharmacologyUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.NIHBethesdaUSA

Personalised recommendations